ALK rearrangements occur in about 4-5% of patients with NSCLC1
Caucasian and Asian populations1
ALK rearrangements have been identified in approximately 4-5% of patients with NSCLC.1 This represents potentially 40,000 new cases of ALK+ NSCLC worldwide each year.1
ALK+ NSCLC
40,000 potential cases each year
Patients with ALK+ NSCLC are most commonly younger, light, or never-smokers and have adenocarcinoma histology2
ALK(+): anaplastic lymphoma kinase (positive); NSCLC: non-small-cell lung cancer.
- Chia PL, et al. Prevalence and natural history of ALK positive non-small-cell lung cancer and the clinical impact of targeted therapy with ALK inhibitors. Clin Epidemiol. 2014;6:423–32.
- Itchins M, et al. Treatment of ALK-rearranged non-small cell lung cancer: a review of the landscape and approach to emerging patterns of treatment resistance in the Australian context. Asia Pac J Clin Oncol. 2017;13:3–13.